NCT05686551 ACTIVE NOT RECRUITING GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Hoffmann-La Roche
NCT06826612 RECRUITING A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
Hoffmann-La Roche
NCT07339514 ACTIVE NOT RECRUITING A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
ExoRNA Bioscience
NCT06254482 ACTIVE NOT RECRUITING An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
Novartis Pharmaceuticals
NCT04120493 ACTIVE NOT RECRUITING Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
UniQure Biopharma B.V.
NCT05541627 ACTIVE NOT RECRUITING A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)
NCT05822908 RECRUITING A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
Vico Therapeutics B. V.
NCT06853743 RECRUITING The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
Oslo University Hospital
NCT05243017 ACTIVE NOT RECRUITING Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
UniQure Biopharma B.V.
NCT05509153 RECRUITING A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Western Sydney Local Health District
NCT04478734 RECRUITING Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT05358717 COMPLETED A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
PTC Therapeutics
NCT03252535 COMPLETED Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Azidus Brasil
NCT05358821 COMPLETED 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Supernus Pharmaceuticals, Inc.
NCT05107128 COMPLETED A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Supernus Pharmaceuticals, Inc.
NCT05032196 COMPLETED Study of WVE-003 in Patients With Huntington's Disease
Wave Life Sciences Ltd.
NCT05111249 TERMINATED A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
Novartis Pharmaceuticals
NCT04201834 COMPLETED Risperidone for the Treatment of Huntington's Disease Involuntary Movements
University of Rochester
NCT06469853 COMPLETED Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients
Medibiofarma S.L.
NCT02453061 COMPLETED A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
Institut National de la Santé Et de la Recherche Médicale, France
NCT03515213 COMPLETED Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
University of California, Irvine
NCT02507284 COMPLETED Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Azevan Pharmaceuticals
NCT04514367 COMPLETED An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
Annexon, Inc.
NCT02481674 COMPLETED A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Vaccinex Inc.
NCT03225846 TERMINATED Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Wave Life Sciences Ltd.
NCT03980938 TERMINATED Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
EIP Pharma Inc
NCT03342053 COMPLETED A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
Hoffmann-La Roche
NCT03225833 TERMINATED Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Wave Life Sciences Ltd.
NCT04617860 TERMINATED Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Wave Life Sciences Ltd.
NCT04617847 TERMINATED Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Wave Life Sciences Ltd.
NCT02494778 TERMINATED A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Prilenia
NCT02519036 COMPLETED Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
Ionis Pharmaceuticals, Inc.
NCT03306888 COMPLETED Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD
Teachers College, Columbia University
NCT02342548 TERMINATED Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
Pfizer